EGFR and cancer: These findings are in agreement with and extend the results from other cancer cell models, including pancreatic (Yin et al, 2007), colorectal (Buck et al, 2007a, 2007b), head and neck (Frederick et al, 2007), bladder (Shrader et al, 2007) and breast (Buck et al, 2007a, 2007b) cancers, in which expression of EMT markers correlated with lack of activity of EGFR targeting drugs.